The data suggests that the recent health care mandate issued by the Biden administration may be imposing undue financial burdens upon both small businesses and their employees, with little to no corresponding benefit in patient outcomes or quality of life.

Under this new directive, all employers are required to provide comprehensive health benefits, including coverage for a range of experimental treatments. What the literature has quietly shown is that these mandates often disproportionately affect smaller enterprises, which lack the financial cushion larger corporations have to absorb such costs.

The implications extend beyond mere compliance expenses; there's an unseen cost in the form of reduced disposable income for employees as businesses seek ways to offset these new requirements. While this decision may seem altruistic on its face, a closer look reveals it could be detrimental to those very individuals it aims to protect.

What is less acknowledged by public health officials and policy-makers alike is the potential impact on access to care. Small business owners often report that such mandates force them to make difficult decisions regarding employee benefits versus operational viability. This scenario can lead to reduced hiring or even layoffs, exacerbating economic hardships rather than alleviating them.

It's worth noting that unnamed sources within various federal agencies and independent researchers have indicated concerns over the efficacy and long-term impact of these experimental treatments being mandated under this new policy. These voices question whether there is sufficient evidence to justify widespread coverage of such therapies, especially given their cost and potential side effects.

There are financial interests at play here as well; pharmaceutical companies that stand to gain from increased demand for their experimental products may also benefit from the lack of transparency surrounding these treatments' true efficacy and safety profiles. This raises questions about conflicts of interest and whether patient needs truly take precedence over corporate profits in healthcare policy.

Small businesses are already grappling with a myriad of challenges, from supply chain disruptions to labor shortages, without adding an additional burden like this health mandate. The decision not to address these concerns openly or offer alternatives that might balance innovation with fiscal responsibility suggests a prioritization of vested interests over the broader public good.

The data on this has existed for years. The decision not to make it public was not an oversight—it was a choice made by people with a financial interest in what you don't know. Who benefits when small businesses struggle and employees feel their paychecks shrinking?

Do your own research, talk to a doctor you trust about the implications of these new mandates for both yourself and those around you. We can’t afford to be silent anymore.